

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF OSA

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors (the “Board”) of the Company is pleased to announce that on 2 February 2026, the application for the clinical trial of UBT251 Injection, a class 1 innovative new drug self-developed by The United Bio-Technology (Hengqin) Co., Ltd. (“United Biotechnology”), a wholly-owned subsidiary of the Company, on indication of moderate to severe obstructive sleep apnea (“OSA”) with obesity was approved by China National Medical Products Administration with reference number of CXHL2501306.

UBT251 Injection is a multi-target peptide receptor agonist independently developed by United Biotechnology that, by acting on the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulintropic polypeptide (GIP) receptor and the glucagon (GCG) receptor, lowers blood glucose and inhibits weight gain. GLP-1-based weight-loss drugs, among others, are expected to fill the significant unmet clinical need in the treatment of OSA.

In addition, Phase II clinical trials of UBT251 Injection on indications of overweight or obesity, type 2 diabetes, metabolic-associated steatohepatitis (“MASH”), and chronic kidney disease (“CKD”) have been initiated in China.

As the first chemically synthesized GLP-1R/GIPR/GCGR triple agonist new drug in China, UBT251 positions the Company as a key player in the R&D of this type of drug. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 3 February 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.